Cargando…
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
BACKGROUND: The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain. METHODS: Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response. RESULTS: Three hundred twenty-two...
Autores principales: | Cohen, Jeffrey A, Bermel, Robert A, Grossman, Cynthia I, Hersh, Carrie M, Hyland, Megan, Mowry, Ellen M, Naismith, Robert, Naylor, Maria L, Nicholas, Jacqueline, Rajbhandar, Rajani, Singh, Carol M, Tintorè, Mar, Zabalza, Ana, Ziemssen, Tjalf, Williams, James R, Montalban, Xavier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131404/ https://www.ncbi.nlm.nih.gov/pubmed/34994577 http://dx.doi.org/10.1177/13524585211061343 |
Ejemplares similares
-
Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS)
por: Mowry, Ellen M., et al.
Publicado: (2020) -
Outcome Measures in Multiple Sclerosis
por: Bermel, Robert, et al.
Publicado: (2014) -
Digital Innovation in Multiple Sclerosis Management
por: Ziemssen, Tjalf, et al.
Publicado: (2021) -
Molecular biomarkers in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2019) -
Multiple sclerosis management during the COVID-19 pandemic
por: Moss, Brandon P, et al.
Publicado: (2020)